Bone Biologics Signs Option to License Nell-1 Bone Growth Factor for Use in Osteoporosis

Bone Biologics signed an option agreement with UCLA for an opportunity to exclusively license the use of Nell-1 bone growth factor in the treatment of osteoporosis.

Bone Biologics is presently funding the development of a Nell-1-based bone graft substitute for spinal fusion, also under exclusive license from UCLA. Nell-1 has demonstrated...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us